Effect of Honey on Nocturnal Cough and Sleep Quality: A Double-blind, Randomized, Placebo-Controlled Study

OBJECTIVE The aim of this study was to assess in-hospital (immediate) postoperative pain scores and analgesic consumption (primary goals) and preoperative anxiety and sleep quality (secondary goals) in patients who underwent craniotomy and were treated with pregabalin (PGL). Whenever possible, out-of-hospital pain scores and analgesics usage data were obtained as well. METHODS This prospective, randomized, double-blind and controlled study was conducted in consenting patients who underwent elective craniotomy for brain tumor resection at Tel Aviv Medical Center between 2012 and 2014. Patients received either 150 mg PGL (n = 50) or 500 mg starch (placebo; n = 50) on the evening before surgery, 1.5 hours before surgery, and twice daily for 72 hours following surgery. All patients spent the night before surgery in the hospital, and no other premedication was administered. Opioids and nonsteroidal antiinflammatory drugs were used for pain, which was self-rated by means of a numerical rating scale (score range 0–10). RESULTS Eighty-eight patients completed the study. Data on the American Society of Anesthesiologists class, age, body weight, duration of surgery, and intraoperative drugs were similar for both groups. The pain scores during postoperative Days 0 to 2 were significantly lower in the PGL group than in the placebo group (p < 0.01). Analgesic consumption was also lower in the PGL group, both immediately and 1 month after surgery. There were fewer requests for antiemetics in the PGL group, and the rate of postoperative nausea and vomiting was lower. The preoperative anxiety level and the quality of sleep were significantly better in the PGL group (p < 0.01). There were no PGL-associated major adverse events. CONCLUSIONS Perioperative use of twice-daily 150 mg pregabalin attenuates preoperative anxiety, improves sleep quality, and reduces postoperative pain scores and analgesic usage without increasing the rate of adverse effects. Clinical trial registration no.: NCT01612832 (clinicaltrials.gov)

Download Full-text

Melatonin Supplementation for Six Weeks Had No Effect on Arterial Stiffness and Mitochondrial DNA in Women Aged 55 Years and Older with Insomnia: A Double-Blind Randomized Controlled Study

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18052561 ◽

2021 ◽

Vol 18 (5) ◽

pp. 2561

Author(s):

Yonghwan Kim ◽

Hee-Taik Kang ◽

Duk-Chul Lee

Keyword(s):

Insulin Resistance ◽

Mitochondrial Dna ◽

Placebo Group ◽

Arterial Stiffness ◽

Sleep Quality ◽

Copy Number ◽

Quality Index ◽

Controlled Study ◽

Double Blind ◽

Randomized Controlled

Melatonin is a hormone produced in the pineal gland that controls sleep and circadian rhythm. Some studies have reported antioxidant and anti-inflammatory effects of melatonin that could benefit cardiometabolic function; however, there is a lack of evidence to support these assertions. The aim of this study was to investigate whether melatonin has beneficial effects on arterial stiffness and mitochondrial deoxyribonucleic acid (DNA) in humans. Methods: This study was designed as a double-blind randomized controlled study. Thirty-eight healthy women aged 55 years and older were enrolled. All had insomnia (Pittsburgh Sleep Quality Index (PSQI) ≥ 5), not treated with any medications, for at least three months before enrollment. Subjects were divided into a melatonin and a placebo group according to melatonin supplementation. The melatonin group took 2 mg melatonin every night for six weeks. The cardio–ankle vascular index (CAVI) was used as an indicator of arterial stiffness. After six weeks, CAVI, mitochondrial DNA (mtDNA) copy number in white blood cells (WBCs), and other metabolic indices, such as homeostasis model assessment of insulin resistance (HOMA-IR), were checked. Results: Sleep quality index using PSQI was improved in the melatonin group from a score of 11 to 8 (p = 0.01), but did not change significantly in the control group. However, there was no significant intergroup difference in PSQI. Systolic blood pressure (SBP) decreased in the melatonin group from 135 to 128 mmHg (p = 0.015), while remaining stable in the placebo group. Right CAVI, mitochondrial DNA copy number, and HOMA-IR were not altered in either group. There were no intergroup differences in CAVI, mtDNA, HOMA-IR, or SBP between baseline and week six. Conclusions: We found no evidence that melatonin supplementation improved cardiometabolic parameters like arterial stiffness, mtDNA, or insulin resistance compared to the placebo between baseline and week six. Sleep quality was improved in the melatonin group. Further research, including longer-term studies with higher doses of melatonin, is warranted.

Download Full-text

Effect of honey on nocturnal cough and sleep quality: a double-blind, randomized, placebo-controlled study1)

Nederlands Tijdschrift voor Evidence Based Practice ◽

10.1007/s12468-014-0026-6 ◽

2014 ◽

Vol 12 (3) ◽

pp. 14-15

Author(s):

Bea Tiemens

Keyword(s):

Sleep Quality ◽

Double Blind ◽

Nocturnal Cough

Download Full-text

Effects of Saffron Extract on Sleep Quality: A Randomized Double-Blind Controlled Clinical Trial

Nutrients ◽

10.3390/nu13051473 ◽

2021 ◽

Vol 13 (5) ◽

pp. 1473

Author(s):

Barbara D. Pachikian ◽

Sylvie Copine ◽

Marlène Suchareau ◽

Louise Deldicque

Keyword(s):

Sleep Quality ◽

Sleep Duration ◽

Controlled Study ◽

Controlled Clinical Trial ◽

Double Blind ◽

Time In Bed ◽

Nutritional Strategy ◽

Sf 36 ◽

Quality Sleep ◽

Saffron Extract

A saffron extract has been found to be effective in the context of depression and anxiety, but its effect on sleep quality has not been investigating yet using objective approaches. For this purpose, a randomized double-blind controlled study was conducted in subjects presenting mild to moderate sleep disorder associated with anxiety. Sixty-six subjects were randomized and supplemented with a placebo (maltodextrin) or a saffron extract (15.5 mg per day) for 6 weeks. Actigraphy was used to collect objective data related to sleep quality at baseline, at the middle and at the end of the intervention. Sleep quality was also assessed by completion of the LSEQ and PSQI questionnaires and quality of life by completion of the SF-36 questionnaire. Six weeks of saffron supplementation led to an increased time in bed assessed by actigraphy, to an improved ease of getting to sleep evaluated by the LSEQ questionnaire and to an improved sleep quality, sleep latency, sleep duration, and global scores evaluated by the PSQI questionnaire, whereas those parameters were not modified by the placebo. In conclusion, those results suggest that a saffron extract could be a natural and safe nutritional strategy to improve sleep duration and quality.

Download Full-text

Effect of A Novel Formulated Food, Night CalmTM, On Sleep Quality and Mood in Healthy Adults with Self- Reported Poor Sleep: A Randomized, Double-Blind, Placebo-Controlled Study

American Journal of Biomedical Science & Research ◽

10.34297/ajbsr.2021.11.001674 ◽

2021 ◽

Vol 11 (5) ◽

pp. 430-436

Author(s):

Dan Cheng

Keyword(s):

Sleep Quality ◽

Healthy Adults ◽

Controlled Study ◽

Poor Sleep ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Metabarcoding analysis of gut microbiota of healthy individuals reveals impact of probiotic and maltodextrin consumption

Beneficial Microbes ◽

10.3920/bm2020.0137 ◽

2021 ◽

Vol 12 (2) ◽

pp. 121-136

Author(s):

M. Calgaro ◽

M. Pandolfo ◽

E. Salvetti ◽

A. Marotta ◽

I. Larini ◽

...

Keyword(s):

Gut Microbiota ◽

Sleep Quality ◽

Mood State ◽

Bifidobacterium Longum ◽

Controlled Study ◽

Microbiota Composition ◽

Healthy Individuals ◽

Double Blind ◽

Positive Effects ◽

The Impact

In a previously published double-blind, placebo-controlled study, we showed that probiotics intake exerted a positive effect on sleep quality and a general improvement across time in different aspects of the profile of mood state, like sadness, anger, and fatigue in 33 healthy individuals. The present work investigates the impact of the probiotic product, constituted of Limosilactobacillus fermentum LF16, Lacticaseibacillus rhamnosus LR06, Lactiplantibacillus plantarum LP01 (all former members of Lactobacillus genus), and Bifidobacterium longum 04, on the gut microbiota composition of the same cohort through a metabarcoding analysis. Both the placebo and probiotic treatments had a significant impact on the microbiota composition. Statistical analysis showed that the microbiota of the individuals could be clustered into three groups, or bacteriotypes, at the baseline, and, inherently, bacterial compositions were linked to different responses to probiotic and placebo intakes. Interestingly, L. rhamnosus and L. fermentum were retrieved in the probiotic-treated cohort, while a bifidogenic effect of maltodextrin, used as placebo, was observed. The present study shed light on the importance of defining bacteriotypes to assess the impact of interventions on the gut microbiota and allowed to reveal microbial components which could be related to positive effects (i.e. sleep quality improvement) to be verified in further studies.

Download Full-text